El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 

Prognostic value of IL-6 in the localized prostatic cancer

dc.contributor.authorAlcover García, Juan
dc.contributor.authorFilella Pla, Xavier
dc.contributor.authorLuque Gálvez, Ma. Pilar
dc.contributor.authorMolina, Rafael (Molina Porto)
dc.contributor.authorIzquierdo Reyes, Laura
dc.contributor.authorAugé Fradera, Josep Maria
dc.contributor.authorAlcaraz Asensio, Antonio
dc.date.accessioned2019-04-10T18:10:16Z
dc.date.available2019-04-10T18:10:16Z
dc.date.issued2010-10
dc.date.updated2019-04-10T18:10:16Z
dc.description.abstractAIM: The usefulness of interleukin 6 (IL-6) and its soluble receptor IL-6sR in the prediction of the biochemical recurrence was evaluated in patients with prostate cancer treated with radical prostatectomy. PATIENTS AND METHODS: IL-6 and sIL-6R serum levels were measured in 96 patients with prostate cancer. RESULTS: Using the log-rank test, it was evident that patients with preoperative serum levels of IL-6 higher than 1.2 pg/ml had a significantly increased probability of biochemical recurrence (p=0.031). We also observed that the Gleason score was associated with the risk of progression (p=0.033), but no relation was observed with TNM classification, PSA, % free PSA or sIL-6R. In a multivariate analysis, only IL-6 serum levels remained as a predictor of biochemical recurrence (p=0.040). CONCLUSION: The results presented here demonstrated the usefulness of IL-6 in predicting the biochemical progression of prostate cancer, pointing towards an association between inflammation and the aggressiveness of the tumor.
dc.format.extent4 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec621775
dc.identifier.issn0250-7005
dc.identifier.pmid21036766
dc.identifier.urihttps://hdl.handle.net/2445/132010
dc.language.isoeng
dc.publisherInternational Institute of Anticancer Research
dc.relation.isformatofReproducció del document publicat a: http://ar.iiarjournals.org/content/30/10/4369.long
dc.relation.ispartofAnticancer Research, 2010, vol. 30, num. 10, p. 4369-4372
dc.rights(c) International Institute of Anticancer Research, 2010
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
dc.subject.classificationCàncer de pròstata
dc.subject.classificationTumors
dc.subject.classificationMarcadors tumorals
dc.subject.otherProstate cancer
dc.subject.otherTumors
dc.subject.otherTumor markers
dc.titlePrognostic value of IL-6 in the localized prostatic cancer
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
621775.pdf
Mida:
2.67 MB
Format:
Adobe Portable Document Format